Sana Biotechnology, Inc. (SANA)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$2.56+4.92%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · SANA
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -42.7% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-04 · Compared with 66 industry peers · Company calendar date is not available
SANA — earnings in line
Dated 2026-05-11
Results of Operations and Financial Condition. On May 11, 2026, Sana Biotechnology, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026. A copy of the press release is attached hereto as Exhibit 99.1. The information in this Item 2.02, including the attached Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or othe…
Why it matters: SC451 aims to replace missing insulin-making cells. Early safety, cell survival, and function are the first tests.
Supportive ifEarly SC451 trial updates show cells survive, C-peptide rises, and no safety issue linked to treatment.
Worry ifTrial updates show no C-peptide, loss of the graft, or a serious treatment-linked safety issue.
Why it matters: This is a key step from lab work to testing in people. A delay could push back a main 2026 goal.
Supportive ifSana files the SC451 IND and starts its Phase 1/2 trial by year-end 2026.
Worry ifSana reports that the IND filing or trial start has slipped past year-end 2026.
Why it matters: Sana reported $160.5 million in cash and a runway into mid-2027. Cash use can change that timeline.
Worry ifSana reports cash runway beyond mid-2027 without a new share sale or a lower cash burn.
Less concerning ifSana reports runway ending before mid-2027 or cash burn that shortens the stated runway.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$254 on $10,000 · ±2.5% | How much price usually moves either way. |
| Bad day | $841 loss on $10,000 · 8.4% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,618 loss on $10,000 · 56.2% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.